Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
402,264
result(s) for
"Obesity"
Sort by:
Benchmarking Obesity-Related Competencies in Dietetic Supervised Practice Programs
Background: Registered dietitians (RDs) are an important part of the interdisciplinary team required for effective obesity care. However, the extent of obesity training for RDNs has not been studied. The objective of this study was to benchmark the inclusion and perceived importance of obesity-related competencies in US dietetic supervised practice (SP) programs, which are a required part of clinical training for all RDs. Methods: This cross-sectional survey study was modeled after previous studies of obesity-related medical training. The survey was based on the 2017 interprofessional Provider Competencies on the Prevention and Management of Obesity and was emailed to all 319 SP directors in the US. Participants were asked to rate the extent to which each of the 31 competencies are incorporated into their program using a 4-pt Likert scale. The survey also included questions about barriers. Results: We received 34 responses, representing 10% of SP directors. 55% (n=21) indicated that teaching students about the prevention or treatment of obesity is an intentional program objective. The most commonly included competencies were 'evaluate BMI' and 'perform effectively in an interprofessional team', reported as being covered to a \"great extent\" by 82% and 71% of respondents, respectively. Very few programs reported \"not at all incorporated\" for any competencies; the most frequent were 'potential role of genetics/epigenetics' (15%, n=5) and 'physiology/pathophysiology of obesity' (12%, n=4). 'Perform effectively in an interprofessional team' and 'discuss obesity in a non-judgmental manner' were considered \"very important\" by 94% and 88% of respondents, respectively. The most frequently reported barriers were lack of room in the curriculum and lack of obesity-related rotation sites, reported as a moderate or large barrier by 68% and 53% of respondents, respectively. Conclusions: This study is the first step to understanding the degree to which RDs are trained in obesity, and the perceived importance of obesity training. Some competencies are integrated to a high degree, while others are incorporated very little due to various barriers.
Journal Article
S-309309: A Novel Selective Inhibitor of MGAT2 That Exert Potent Anti-Obesity Effect in DIO Mice
Background: Monoacylglycerol acyltransferase 2 (MGAT2) is an enzyme involved in triglyceride resynthesis of small intestinal epithelial cells. Although some reports indicate that inhibition of MGAT2 would be a promising target for anti-obesity treatment, there are few MGAT2 inhibitors that show a highly effective profile. Therefore, we identified S-309309, which is an oral MGAT2 small molecule inhibitor, and examined its anti-obesity effect and mechanisms in non-clinical study. Methods: In vitro activity of S-309309 was tested using mouse and human MGATs and diacylglycerol acyltransferase (DGATs) enzymes. In vivo anti-obesity effect of S-309309 was evaluated in high fat diet induced obese (DIO) mice by comparison with liraglutide or combination of phentermine/topiramate, which used in clinical for obesity. In addition, combination studies with liraglutide or semaglutide and mechanism study of S-309309 anti-obesity effect were also conducted in DIO mice. Results: S-309309 had potent inhibitory activity for human and mouse MGAT2 with IC50 values of <30 nM. On the other hand, IC50 values of S-309309 on human MGAT3, DGAT1 and DGAT2 were more than 100 pM. S-309309 showed a potent and dose-dependent anti-obesity effect in DIO mice, and the effect was stronger than that of liraglutide and combination of phentermine/topiramate. When combination with liraglutide or semaglutide, the combinations exhibited stronger anti-obesity effect than single-agent therapy of liraglutide, semaglutide or S-309309 in DIO mice. Furthermore, we demonstrated that S-309309 had multiple mechanisms of action such as suppression of feeding, delayed lipid absorption into the body and increased energy expenditure. Conclusions: S-309309 showed a significant and selective inhibitory activity on human and mouse MGAT2 in vitro and a potent antiobesity effect with multiple mechanisms in DIO mice. These results suggest the attractive therapeutic potential of S-309309 for obesity treatment.
Journal Article
Effects of a Short- and Long-term Fast on Reward Neural Activity in Patients With Obesity
Background: Obesity is a complex disease characterized by dysregulation in energy intake. The reward circuitry of the central nervous system is essential in food intake regulation. However, the effects of a short- and long-term fast on reward activity and subsequent caloric intake are not well understood. Methods: The neuroimaging food paradigm consisted of three pseudo-continuous arterial spin labeling (pCASL) MRI scans during an ad libitum nutrient drink (Ensure®) test (NDT) (drinking until maximal fullness). The first scan was performed before starting the NDT (Hunger) after a >12-hr (long-term) overnight fast or a 4-hr (short-term fast) after a 380-kcal standard breakfast, the second scan after reaching maximal fullness (Satiation), and the third scan 30-min after satiation (Satiety). Semiquantitative cerebral blood flow (CBF) maps in mL/100 gr brain/min were calculated from the pCASL data. Brain regions of interest (right and left caudate, putamen, and nucleus accumbens [NAc]) were segmented from T2 volumes using Freesurfer (run_first_all) and used to mask CBF maps to determine the average CBF in each region. Changes in CBF were used as a proxy of neural activity. Results: A total of 43 patients with obesity (mean±SD age 37±10 years, body-mass index [BMI] 35.1±4.4kg/m2, 72% females) completed the study, 29 in the long-term fast and 14 in the short-term fast group. The long-term fast group consumed 1306±125 kcal in the NDT compared with 1125±301 kcal in the short-term fast (p=0.1). The short-term fast group had a significantly lower activity (CBF) in the left and right NAc, and left and right caudate nucleus during hunger, satiation, and satiety, and in the left and right putamen only at hunger. Conclusions: Recent (<4hrs) caloric intake decreases reward neural activity but not ad libitum energy intake in patients with obesity.
Journal Article
Contemporary Patterns of Financial Toxicity Among Patients With Obesity
Background: Obesity is a complex multifactorial disease associated with debilitating chronic comorbidities and increased healthcare costs. Due to an array of factors such as weight bias and discrimination, patients with obesity are also more likely to be unemployed and to earn less than their counterparts without obesity. This study aimed to evaluate patterns of financial toxicity among patients with obesity. Methods: Using the National Health Interview Survey from 2013 to 2018, patient demographics and self-reported financial metrics were collected or calculated for patients with obesity (body mass index of 30 or greater), including financial hardship from medical bills, financial distress, food insecurity, and cost-related medication (CRM) non-adherence. Multivariable logistic regression was used to assess factors associated with increased financial hardship. Results: 72,254 patients with obesity were included in this study. 22.3% faced some financial hardship due to medical bills, of which 55.8% could not pay these bills. Obesity was associated with higher odds of financial hardship from medical bills (odds ratio [OR] 1.27, 95% confidence interval [CI] 1.23-1.32) with similar trends for financial distress (OR 1.13, 95% CI 1.09-1.17), food insecurity (OR 1.19, 95% CI 1.14-1.24)=, and CRM non-adherence (OR 1.23, 95% CI 1.18-1.28, p<0.001 for all). Financial hardship among patients with obesity was also associated with being male (OR 1.28, 95% CI 1.21-1.35), Black (OR 1.31, 95% CI 1.22-1.41), uninsured (OR 2.11, 95% CI 1.96-2.27), and in poor self-reported health (AOR 5.88, 95% CI 5.18-6.67, p<0.001 for all). Conclusions: A substantial proportion of adults with obesity struggle with paying their medical bills and suffer from high rates of financial distress, food insecurity, and CRM non-adherence. Further research into the causal and potentially actionable mechanisms that lead patients with obesity to experience financial toxicity should be pursued. Public policy reform may represent a critical lever to ease the burden of financial hardship for these patients.
Journal Article
Medication Possession Ratio for Anti-Obesity Medication at VA Greater Los Angeles Healthcare System
Background: Medication Possession Ratio (MPR) measures adherence and persistence on anti-obesity medication (AOM). Previous studies have shown poor compliance to AOM. An MPR of 80% historically suggests acceptable level of adherence. The aim of our study was to illustrate MPR rate in our MOVE! Program at VA Greater Los Angeles Healthcare System (VAGLAHS). Methods: Patients were identified if they filled any FDA approved AOM (phentermine/topiramate, naltrexone/bupropion, orlistat, liraglutide, or lorcaserin) from January 2006 to June 2020. Patients were excluded if they only filled AOM once. MPR was calculated as the sum of day supply of medication for all fills over number of days from first fill to last fill. Data was extracted from VAs Corporate Data Warehouse. Results: A total of 280 Veterans were included in our MPR calculation. MPR for orlistat was the least at 56% (n=160, range 5-200%), followed by low dose phentermine/topiramate at 76% (n=97, range 15-130%), liraglutide at 82% (n=73, range 35-153%), high dose phentermine/topiramate at 83% (n=38, range 17-162%), lorcaserin at 85% (n=35, range 33-120%), and lastly naltrexone/bupropion with the highest MPR at 92% (n=16, range 34-200%). Average days between first and last fill in order from shortest to longest duration were 184 days on naltrexone/bupropion, 249 days on lorcaserin, 323 days on high dose phentermine/topiramate, 333 days on low dose phentermine/topiramate, 364 days on liraglutide, and 445 days on orlistat. Conclusions: There were varying ranges of MPR of each medication, however we saw a high percentage of adherence, which would conflict with existing poor adherence studies, except for orlistat, in our MOVE! Program at our institution. We had a relatively long duration of therapy as well on AOMs suggesting efficacy and tolerability as we move forward in treating obesity as a chronic disease state.
Journal Article